Story thread · 2 reports / 2 sources

Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

biopharmadive.com · 13hShare

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.

First report: Akeso details survival win for its PD-1xVEGF drug versus Keytruda — endpts.com, 2d